The launch of the 'East Data West Computing' project has had an impact on data center enterprises' green certificates, green electricity, and carbon trading behaviors. What opportunities have arisen as a result? What proportion do data center enterprises hold in these markets? Can green certificate and green electricity trading further promote the true implementation of 'East Data West Computing'? How should data center enterprises participate in green electricity trading? As major energy consumers, what can data center enterprises do for the green electricity and green certificate trading market?     Frost & Sullivan Frost & Sullivan Mr. Lu Jing, Partner and Managing Director of Frost & Sullivan Greater China, was interviewed. 21 Interviewed by Century Economic Report, for joint discussion    The above topic    . 21 Century Economic Report Q What impact has the launch of the 'East Data, West Computing' project had on green certificates, green electricity, and carbon trading behaviors for data center enterprises? What opportunities have arisen as a result? What proportion do data center enterprises account for in these markets? The launch of the 'East Data West Computing' project marks a national policy setting the tone for the domestic data center industry towards carbon reduction, energy conservation, environmental protection, and rational resource allocation. The trading activities of data center enterprises in the green electricity and green certificate markets as well as carbon trading markets are a direct reflection of their development and transformation towards green and low-carbon industries. As an industry that consumes a large amount of electricity, promoting its high-level or even full use of green electricity is an inevitable choice for the national industrial structure to upgrade and transform towards sustainable development. Therefore, in terms of results, the launch of the 'East Data West Computing' project has heated up the domestic data center industry's interest in green electricity, green certificates, and carbon trading markets, and the continuous warming of this industry in these markets is also foreseeable. In the construction of 'East Data, West Computing', the coordinated development between data center enterprises and the green electricity and green certificate market has provided us with practical cases of green certificates and electricity being implemented in the market economy. This has shifted the focus of China's green electricity and green certificate market from being limited to multinational enterprises with overseas market demand to an organic integration of various players in environmental protection, manufacturing services, and capital markets, providing an excellent model for the future development of the market's model. 2021 In China, the power consumption of data centers reached 2,166 Yidian, 2022 The conservatively estimated annual power consumption is expected to reach 2,700 Yidu scale. Among them 30% The power supply comes from green electricity, that is, the annual consumption of green electricity by data centers in China has exceeded 650 Yidu / Each year, it accounts for approximately 3% . Q Can green certificates and green power transactions further promote the real implementation of 'East Data West Computing'? Some argue that western green energy can enable local data centers to achieve carbon peak and carbon neutrality goals as soon as possible. The excess electricity can be traded with eastern data centers through green power and carbon sink methods. What's your opinion on this? The core of the 'East Data, West Computing' project lies in the rational optimization of China's current data computing power production process by utilizing the rich renewable and environmental resources in western China. PUE Problems such as high values, low environmental benefits, and scattered production capacity have made China's data center industry an advantageous industry that combines service efficiency, environmental benefits, and economic output. Among these, the purchase and use of green electricity by data center enterprises are a core link. Only when the actual implementation of green electricity usage plans in enterprise data centers can truly mark the achievement of the sustainable development goals of the entire industry. On the other hand, green certificate trading is more focused on empowering the early development of projects. By purchasing green certificates, enterprises can not only endorse their own sustainable development planning but also provide effective support for the development of green power generation enterprises. Therefore, it is evident that green certificates and green electricity trading further provide impetus for the implementation of China's 'East Data West Computing' project. Currently, the production of green electricity in the western region mainly meets the local data center's usage needs, and there are few cases where enterprises resell green electricity to third parties. Of course, as renewable energy's penetration rate into the overall energy market increases in the future, there are certain market opportunities for this model of resale through green electricity and carbon sink trading. However, the overall market is still in the exploration phase regarding cooperation models. Q How should data center enterprises participate in green power trading? As major energy consumers, what can data center enterprises do for the green power and green certificate trading market? Data centers mainly participate in the market as buyers of green electricity transactions, mainly through negotiation, matching, and listing to engage in the purchase of green electricity resources in the market. They provide necessary financial and market resources for renewable energy producers. On the other hand, data centers can also provide digital management services for green power generation enterprises through data technology means, and they can be infrastructure providers and transaction data management service institutions upstream of the smart grid industry. Firstly, we believe that data center enterprises should actively participate in the green power and green certificate market transactions to improve their own green power usage rate and follow a sustainable development path for enterprises. On the other hand, data center enterprises can explore potential data service opportunities in the production process of renewable energy to contribute to the development of the green power and green certificate trading market.   * This interview was published in 21 Century Economic Report, reporter: Guo Meiting   The original title is    Data Center Layout Green Power Trading: "East Data, West Computing" has heated up market enthusiasm, and enterprises are looking forward to establishing multi-year, cross-provincial and cross-regional trading rules    (Click on "Read the Original Article" at the end of the text to read the full report).

With the popularity of high-speed hair dryer racing, many domestic hair dryer manufacturers now have relevant technical reserves. Do you think that at present, when comparing with foreign manufacturers such as Dyson, Panasonic, and Philips, there is a significant difference in technical level? Can domestic manufacturers break through in the future?    In addition to technological innovation, many new brands of hair dryers now focus on deploying in new channels, including live e-commerce and Douyin. However, they rarely make efforts in offline channels. What is the reason for this phenomenon, and will it become a weakness in brand development in the future? Frost & Sullivan Frost & Sullivan Frost & Sullivan's consulting analyst for the consumer industry in Greater China, Zhu Renjie, was interviewed by State Grid China and discussed together    Hair dryer industry development    . State Grid of China Q With the popularity of high-speed hair dryer racing, many domestic hair dryer manufacturers now have relevant technical reserves. Do you think that at present, when comparing with foreign manufacturers such as Dyson, Panasonic, and Philips, the technical level gap between domestic manufacturers is significant? Can domestic manufacturers break through in the future? Zhu Renjie Frost & Sullivan Greater China Consumer Industry Consulting Analyst The high-speed hair dryer is characterized by a larger air volume and a more precise temperature control system. It uses lower-temperature but high-speed air to replace the traditional hair dryer's high-temperature and low-speed airflow, thereby better reducing the damage caused by high temperatures to hair. The core components of a high-speed hair dryer include a speed exceeding per minute 10 High-speed motors with ten thousand revolutions per minute and temperature control components. Take the foreign manufacturer Dyson as an example, as early as 1999 In that year, Dyson invested more than 3.5 Billion pounds, and has subsequently applied for 1,000 Remaining related patented technologies. Dyson spends 10% - 15% The sales revenue is used for R&D, while the R&D investment of domestic home appliance brands is generally lower than the total revenue. 5% Under the strategy of high-intensity investment in research and development, Dyson already has 3,000 Multiple patents and more than 500 Invention. In recent years, domestic emerging brands such as Lai Fen and Zhen Wei have successively launched domestic high-speed hair dryers equipped with self-developed motors. Domestic high-speed hair dryer products have approached the technical level of foreign brands, but it will still take time to reverse the concept of 'substitute' in consumers' minds. Domestic brands that can break through and dominate the high-speed hair dryer industry in the future need to possess four characteristics:   Firstly, brands need to clarify their high-end positioning from the very beginning of establishment and make it clear to consumers during marketing; secondly, they require excellent product quality and experience to match the high-end price; thirdly, they need sufficient capital to support the brand's integration of products, services, channels, and marketing; finally, we need domestic brands to practice long-termism and use a persistent and focused attitude to gain industry discourse power. Q In addition to technological innovation, many new brands of hair dryers now focus on deploying in new channels, including live e-commerce and Douyin, but rarely on offline channels. What is the reason for this phenomenon, and will it become a weakness in brand development in the future? Zhu Renjie Frost & Sullivan Greater China Consumer Industry Consulting Analyst In recent years, a clear trend has been an obvious acceleration in the cycle from establishment to brand formation for new consumer enterprises.   The rise of emerging online channels such as Douyin, Rednote, and live e-commerce platforms has also brought a wave of traffic dividends to brands, accelerating their customer acquisition. Certainly, many new consumer brands have quickly become popular with the support of traffic, but these newly popular brands seem to be more fragile than ever. A very important reason is that most new consumer brand enterprises believe in a strong marketing approach that claims miracles, with marketing and revenue 'relying on each other for survival.' Under homogeneous marketing tactics, consumer attention is distracted, and it is difficult for converted customers to form brand recognition. As a result, once the marketing stops, it is hard for customers to repurchase. With the overall e-commerce industry in recent years GMV The slowdown in growth rate, coupled with brands focusing only on online channels, could pose a hidden danger to future sustained growth. Due to the different main categories, customer profiles, channel characteristics, and profit margins of offline channels, this poses a significant challenge to emerging brands that started online. This challenge is not limited to negotiations for entering offline channels; it also includes the development of subsequent coverage channels, differentiated product selection, pricing, and even larger difficulties such as whether R&D design, production supply can keep up.   The overall offline channel layout requires long-term and continuous investment and experience. Without a long-term comprehensive layout, emerging brands will find it difficult to make a significant impact on offline channels in a short period.   * This interview was published in China Power Grid, with Yang Zhimin as the reporter.   Original title:     Is the success of Lai Fen an accident or necessity of high-speed blowers?    (Click the title to read the full report).

VacCon The 5th New Vaccine R&D and Industrialization Forum 2023 year 3 month 3 - 4 day, VacCon The 5th New Vaccine R&D and Industrialization Forum grandly opened at the Crowne Plaza Hotel in Wuhan Optics Valley. 60+ Experts from government regulatory agencies, scientific research experts, scientists, and leaders of leading enterprises in the field of new vaccine development will deliver exciting and engaging speeches and engage in lively discussions. 1000+ The core group of the vaccine industry gathered at this grand event to enthusiastically discuss the application and cases of cutting-edge innovative technologies, aiming to assist in the rapid development of China's vaccine industry.   "Hot Topics and Prospects in Vaccine Industrialization (Regulation / Internationalization) ” Several industry leaders in the vaccine sector will share their insights on the latest trends in immunization programs and vaccine research and development both domestically and internationally, and delve into the construction of international production quality and advanced production practices.   Frost & Sullivan Frost & Sullivan Chen Zhenrong, Director of Healthcare Industry Consulting for Greater China at Frost & Sullivan (referred to as 'Frost & Sullivan'), was invited to attend the event and delivered a keynote speech on 'Research Report on the Current Development and Future Trends of the Human Vaccination Market'. Frost & Sullivan Greater China Healthcare Industry Consulting Director Chen Zhenrong   Chen Zhenrong stated that before the founding of New China, there were only a few vaccines available in China for the prevention of severe infectious diseases such as cowpox and cholera. Due to poor economic and health conditions, frequent wars, and other adverse factors, large-scale and systematic vaccine production and immunization work across the country had not been carried out.   70 Over the years, China has been vigorously promoting planned immunization. Especially after the reform and opening up, the introduction and deepening of market mechanisms in the vaccine industry have led to a rapid increase in the variety of vaccines produced in China. The vaccine industry has also entered a period of rapid development. Looking at the development path of the vaccine industry in accordance with China's vaccination immunization program, it can be basically divided into the early stage of planned immunization, the period of planned immunization, the period of immunization program implementation, and the period of expanding the immunization program. 2005 The State Council's executive meeting in the year passed the 'Regulations on Vaccine Circulation and Immunization Administration', followed by the Ministry of Health's formulation of the 'Work Specifications for Immunization', which have been fully implemented with the national immunization program. With the development of the national economy and the continuous improvement of people's health needs, the scope of the immunization program has been continuously expanded. Chen Zhenrong pointed out, 2019 In [year], the Standing Committee of the National People's Congress passed the Vaccine Administration Law of the People's Republic of China. 2022 In [year], the National Medical Products Administration issued the 'Regulations on the Administration of Vaccine Production and Distribution', further strengthening vaccine management, ensuring vaccine quality and supply, standardizing vaccination programs, promoting the development of the vaccine industry, protecting public health, and maintaining public health security.   At the same time, China's vaccine industry has entered a period of standardized development and is gradually entering the harvest phase. Chen Zhenrong believes that vaccines, as the most cost-effective and effective means of preventing and controlling infectious diseases, have also played an indispensable role in the COVID-19 pandemic. Due to the benefits of pharmacoeconomics, technological innovation, increased public awareness and accessibility, as well as a series of favorable policies related to the vaccine industry, the development of the vaccine industry is booming. The number of clinical research studies on vaccines in China has rapidly increased, gradually narrowing the gap with the United States. More vaccines for different disease prevention using different technical approaches have moved from the clinical research pipeline to practical application.   At present, the Chinese vaccine market is still dominated by Category II vaccines. In recent years, with the launch of blockbuster vaccines such as these, the overall batch release volume has also shown a rapid growth trend.   According to WHO statistics, 2021 still in the year 2,500 Vast numbers of children have not received basic vaccinations, and there are significant disparities in the distribution of immunization resources between countries and within countries. There is a huge demand gap in the global human vaccine market.   2017 The global market size of human vaccines is 277 billion dollars. And this number is to 2021 Year-on-year growth to 460 billion US dollars. It is expected that by 2030 Global vaccine market size could reach 1,310 billion dollars.     2021 In the year, in terms of output value scale, the market scale of vaccines used by Chinese people was close to 930 100 million yuan, accounting for the proportion of the Chinese pharmaceutical market 5.8% As China's vaccine industry enters the harvest phase, it is expected that the industry will enter a stage of rapid development. 2030 years. The output value scale of the vaccine market in China can reach 3,386 100 billion RMB, accounting for approximately the entire pharmaceutical market 12.4% .   Domestic vaccines are in the process of product upgrading, and more high-quality products will become available for selection in the future. As domestic companies continue to advance their research and development products, they will gradually replace existing imported vaccines with domestic ones. 2022 In [year], the World Health Organization announced that China had passed the assessment of the Vaccine National Immunization Programme, which will further stimulate China's vaccine exports to the world.   Chen Zhenrong said that there are some blockbuster vaccine varieties in Category 2 vaccines with significant market potential that deserve attention, including HPV Vaccines, including varicella-zoster vaccine, rabies vaccine, influenza vaccine, pneumococcal vaccine, etc.   First and foremost, it has been very popular in society in recent years HPV vaccine.   2020 year WHO The 'Accelerated Elimination of Cervical Cancer Global Strategy' has been released, with nearly 200 countries including China committing to eliminating cervical cancer. This is also the first time in history that a cancer type has been pledged to be eradicated globally. HPV Viruses can lead to various infections and may trigger cancers including cervical cancer, anal cancer, and head and neck cancer. They can cause immense physical and mental harm to patients. 90% Cervical cancer is all caused by HPV Caused by a viral infection, therefore HPV Vaccination is also one of the core means to eradicate cervical cancer. At the beginning of this year, ten departments including the National Health Commission jointly issued the 'Action Plan for Accelerating the Elimination of Cervical Cancer ( 2023 - 2030 ) Notice, which mentions domestic products that meet the requirements HPV Vaccines are being accelerated in approval and the standardized management of vaccination is strengthened. Currently, many provinces and cities in China have launched pilot programs, with local governments paying for the vaccination of eligible female populations. HPV vaccine.   In terms of the number of ongoing pipelines, China's HPV The number of vaccine research and development projects ranks first globally. Currently, two domestic bivalent vaccines are available. HPV Vaccines have been approved and achieved rapid scale-up, with multiple domestically produced vaccines in different price tiers HPV Vaccines are also about to be approved, and it is expected that there will continue to be a high level of growth in the future.   The second is the herpes zoster vaccine.   The varicella-zoster virus is not unfamiliar to most people. Most of us may have been vaccinated against chickenpox or have had the disease as children. However, data shows that more than 90% There are latent varicella-zoster viruses within this population, and the virus is likely to break out explosively when the human immune system is low. Moreover, post-herpetic neuralgia, that is PHN It may bring very serious economic and psychological burdens. And currently PHN There are no very effective symptomatic treatment methods, so getting vaccinated against shingles is actually about preventing the occurrence and secondary complications of shingles. PNH The most effective prevention method. GSK Recombinant herpes zoster vaccine Shingrix Taking Xing'anlishi as an example, after vaccination 50 People over 70 The protection efficiency for people over [age] is as high as 97.2% and 91.3% Currently available domestically GSK The recombinant zoster vaccine and the attenuated zoster vaccine developed by Baike Biotech have been approved for marketing. The vaccines under research cover attenuated live vaccines, recombinant proteins, mRNA Adeno-associated virus vector, four technical approaches.   From the perspective of clinical progress, it is expected that more domestic varicella-zoster vaccines will be approved for marketing in the future.   Although in terms of the number of batches issued, varicella-zoster vaccine 2021 There was a reduction in the number in [year],   However, it is expected that in the future, as more products are approved for market launch, public awareness improves, and vaccination rates continue to rise, the output value of the herpes zoster vaccine will v A rebounding trend.   In addition, an important focus for the zoster vaccine in China is the expansion of its applicable age range.     When combining the herpes zoster vaccine with HPV When doing a comparative analysis of vaccines, it can be found HPV The actual vaccinated population and purchasers of the vaccine are within the same age range. Therefore, in market promotion, HPV The awareness campaign targeting vaccine uptake is aimed at the same group of people.     But then looking at the herpes zoster vaccine, GSK The current use of Tinosorb in China is limited to 50 Adults aged 65 and above constitute an age gap,     Chinese elderly people are relatively frugal and have a low willingness to get vaccinated. Through consumer interview profiling, it is found that currently   Herpes Zoster Vaccine   The core purchasing group is still 30 At around [age], after purchasing it, I gave it to my elders at home for vaccination.    However, there will be a gap. The elderly have a low level of cognition and are afraid or unwilling to make an appointment online, resulting in many online appointments not being cancelled in the end.     Therefore,   Herpes Zoster Vaccine   If age extension can be achieved, making the vaccinated population and the purchasing population unified, there is hope for a rapid increase in demand.     The third is rabies vaccine.   China is a country with rabies epidemics, with nearly 4,000 Among the 10,000 people exposed to rabies, the current rabies vaccination rate among those who have been exposed is 35% Left and right. In China 99% The rabies cases were caused by bites or scratches from cats and dogs. According to the China Health Statistics Yearbook, 2021 The number of deaths reported from rabies ranked among the top five infectious diseases requiring legal reporting each year. As a typical case of post-exposure prophylaxis, the demand for rabies vaccine remains very high. Affected by the suspension of production by some rabies vaccine manufacturers, 2018 year, 2019 The output value scale of rabies vaccines has decreased in recent years. However, 2020 After a year, with stricter supervision of the vaccine industry, improvements in production technology, increased vaccination rates, and a high-value rabies epidemic   Affected by the entry of new markets, the overall output value scale of rabies vaccines has increased.   The vaccination penetration rate of influenza vaccines has been growing rapidly, at the same time   Influenza vaccines need to be administered annually, which also provides a huge market space for them.   At present, the vaccination rate of influenza vaccines in China is approximately only 3% left and right. For comparison over the same period, taking the United States as an example 50% , taking Canada as an example 40% This also means that there is significant room for development in the output value scale of influenza vaccines in China. last year 8 month CDC The Technical Guidelines for Influenza Vaccination Prevention and Control in China were released (2022 - 2023) It is recommended that key populations and high-risk individuals receive the influenza vaccine. It also mentions that co-infection with influenza viruses and COVID-19 may exacerbate respiratory infection symptoms and impose an even greater physical burden.   recently WHO It has also released recommendations on the types of strains used for influenza vaccines at different valences. The expansion of the target population for quadrivalent vaccines to infants and young children, as well as the gradual replacement of the existing trivalent vaccines, are becoming trends.   Finally, there is the pneumococcal vaccine. The issue of pneumococcal resistance has actually always been a major concern in public health.   The incidence of cross-resistance to commonly used antibiotics, that is, multidrug resistance, among pneumococci is as high as 80% , greatly increasing the difficulty and cost of treatment. Currently, the product types of pneumococcal vaccines include 13 price 23 There are two main categories of vaccines. These vaccines can be administered to children and the elderly respectively, and they can effectively reduce the mortality rate caused by pneumococcal infections. They offer good cost-effectiveness, thus their output value scale has also witnessed rapid growth. 2017 Year-end 2021 The compound annual growth rate for the year is 74% .   The core driving force for the development of the pneumococcal vaccine market also comes from the increasing public awareness of this type of vaccine.   At present, there are still significant differences in the vaccination rates of pneumococcal vaccines among different regions in China. According to literature statistics, the differences between different regions range from 1%-40% Not equal. 2019 Since the beginning of this year, many domestically produced pneumococcal vaccines have been successively approved for market release. Compared to imported vaccines, domestic vaccines offer a price advantage and have also raised the upper age limit for eligible populations, further amplifying market demand. Local disease control centers have also issued documents, providing guiding opinions on the vaccination of pneumococcal vaccines. They support and encourage areas with conditions, especially large cities, to learn from the experiences of Beijing and Shenzhen and implement the vaccination of pneumococcal vaccines as a policy for benefiting the people. As the speech was coming to an end, Chen Zhenrong made further analysis of the capital performance in the vaccine industry. Under the impact of the COVID-19 pandemic, cooperation among domestic and international vaccine companies on the development of COVID-19 vaccines has accelerated significantly, which has also promoted collaboration in other disease prevention areas. In terms of technical approaches, mRNA Vaccines and recombinant protein vaccines are two major technical routes that have become hotspots for collaboration. At the same time, preventive vaccines are gradually shifting towards the development of therapeutic vaccines.   From the perspective of the capital market,   Local enterprises have gone through a period of accumulation and then made a breakthrough, accelerating their listing pace. Meanwhile, companies have also completed rapid layout in key directions through mergers and acquisitions.   Recommended Reading   About Frost & Sullivan's Healthcare Practice   The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences sector. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.

2020 - 2022 In the year, under the impact of global public health events, the protective glove industry at home and abroad underwent significant changes. 2023 In [year], as terminal procurement sentiment returned to rationality and the demand pattern in the downstream sector changed, the protective glove market faced new challenges and opportunities. Technological breakthroughs in the industry, product quality improvement, cost-price control, and diversified development became key factors in corporate competition. Against this backdrop, 3 month 1 day after tomorrow 2 On the day, sponsored by Shandong Longzhong Information Technology Co., Ltd. and co-organized by Shandong Ruibang Intelligent Equipment Co., Ltd., “ 2023 The 'Nianlongzhong Information China Protective Gloves Supply and Demand Exchange Conference' was successfully held in Zibo, Shandong.   Frost & Sullivan Frost & Sullivan Cai Yufan, consulting manager of Frost & Sullivan's Greater China region, was invited to attend the conference and delivered a speech on the current market situation and development trends of disposable gloves. Consulting Manager, Greater China, Frost & Sullivan Cai Yufan As a commonly used protective item, disposable gloves can effectively prevent cross-infection and are suitable for various occasions. According to quality grade and purpose, they can be divided into medical-grade and non-medical-grade. Medical-grade gloves refer to products that need to meet the quality certification system or access standards of the target country's medical market. They are mainly used in fields such as medical surgery, medical examinations, and medical care. Disposable medical gloves are currently mainly classified into PVC There are three categories: gloves, latex gloves, and nitrile gloves. Cai Yufan stated that after the mutation of the novel coronavirus, global cases surged significantly, and the domestic epidemic situation became complex. While accelerating inventory consumption, the demand for disposable gloves was released again, driving the steady growth of the glove market. Data shows that since the outbreak of the COVID-19 pandemic, there has been a significant increase in the demand for disposable gloves for long-term care and emergency rescue. 2021 The global sales volume of disposable gloves reached approximately 7,670 100 million, estimated 2026 Its annual sales volume will reach 11,503 Hundreds of millions. Affected by the continuous increase in the sales volume and rapid price hikes of disposable gloves, 2021 The global sales revenue of disposable gloves for the year was from 2017 approximately 75 Billion dollars rose rapidly to 2021 The year's promise 264 billion US dollars, with an annual compound growth rate during that period reaching 37.0% . In the post-pandemic era, the disposable glove market has gradually returned to normal. The supply and demand relationship and market environment have changed, leading to reduced corporate revenue and profits. Some small and medium-sized manufacturers that entered the market during the pandemic will be gradually phased out. At the same time, with the increasing health awareness of people, it is expected that market demand will experience permanent growth, and the market will continue to grow steadily in the future. Cai Yufan pointed out, 2022 Over the past year, some countries and regions have still been severely affected by the COVID-19 pandemic, leading to a continued strong demand for disposable gloves. The industrial reshaping under the pandemic and the increasing demand for permanent gloves have had varying degrees of impact on regions around the world. Developed regions such as Europe and America    The population has a relatively high standard of living and income, coupled with strict public health regulations. This region has always been the world's largest consumer of gloves and will continue to be a major export area in the future. china    yes PVC The largest producer of gloves, with domestic enterprises gradually expanding the production capacity of nitrile gloves, is expected to further seize market share in the future by leveraging its strong supply chain advantage. In addition, the outbreak of the COVID-19 pandemic has greatly enhanced the health protection awareness of Chinese residents, leading to a gradual increase in per capita glove consumption. The release of a series of new policies by the Chinese government has also promoted the standardization process of glove use. Relying on the advantages of rubber-producing countries, the main producers of latex gloves and nitrile gloves are concentrated in   Malaysia.   In the post-pandemic era, regions such as Vietnam will attract a group of overseas manufacturers to invest in setting up factories due to their low labor costs and policy incentives. For emerging markets such as the Middle East and South America,    The objective demand for medical supplies reserves in various countries is continuously increasing, and public health protection awareness is constantly strengthening. The incremental demand during the pandemic is also expected to settle into a long-term increase over the coming years. Subsequently, Cai Yufan analyzed the production and sales environment of disposable gloves.   She pointed out that the outbreak of global health incidents in the past three years has led to a surge in demand for disposable gloves. With rising raw material prices and a lack of production capacity, the average selling price of disposable gloves soared; as treatment methods such as vaccines were promoted, the epidemic was gradually brought under control, glove demand normalized, and glove prices returned to a rational range;   Due to capacity expansion and the gradual return of demand to stability, the market is facing a new situation where supply exceeds demand temporarily. Currently, the sales prices of some channels have approached pre-pandemic levels.     "The outbreak of the epidemic has brought new development opportunities to enterprises,   Glove manufacturers establish a comprehensive supply chain system to meet the product demands of different markets around the world.     Cai Yufan further explained that previously, affected by the pandemic, factors such as fluctuations in upstream raw material prices, stagnation in logistics system operations, and insufficient enterprise start rates led to a short-term increase in glove prices. However, many leading enterprises have actively seized market opportunities over the past three years or more, gaining sufficient cash flow from high profits. At the same time, they have adopted various methods to cope with market fluctuations, including expanding production capacity and reducing unit costs; integrating upstream raw material resources and logistics systems to ensure stable supply of their own raw materials and product improvement. In response to the innovation in the field of protection services during the later stages of the epidemic, Cai Yufan proposed that enterprises can maintain their long-term core competitiveness in the industry by continuously deploying new protection product areas, strengthening overseas factory construction to adjust business centers, and improving production processes and labor productivity. On the one hand, factors such as market supply and demand changes, intensified industry competition, tightened policy approvals, and Sino-US trade frictions have increased the costs of production and operation for enterprises.   Can be fully utilized    Vietnam and other Southeast Asian countries, with their high-quality resources and preferential policies, are building new production lines to adjust the global business layout focus through overseas logistics distribution. On the other hand, the pandemic has heightened people's awareness of protection, leading to an increase in the use of disposable gloves in non-medical scenarios. This will be more conducive for manufacturers to explore domestic markets. For instance, some manufacturers have established a multi-level marketing model that combines direct sales and distribution based on the characteristics of the current market and future market expansion directions. They use the direct sales model to build corporate brand value and the distribution model to lay out operational sales channels to expand their visibility.

2 month 25 day 2022 Nanjing Overseas High-level Talents Innovation and Entrepreneurship Competition Finals 2023 The city-wide Open Innovation Work Promotion Meeting was held at the Nanjing Economic and Technological Development Zone. With the theme of 'Incorporating Global Intelligence, Together for an Innovative Future', this conference aimed to build a bridge for overseas talents, promote international technology and talent exchanges; by deepening innovation cooperation with key countries, it seeks to stimulate the innovative vitality of various entrepreneurial entities and enterprises, and advance the city's open innovation cooperation to deeper levels.   Global Overseas High-Level Talent Registration for the Competition 170 Selected from multiple projects 30 The project held a wonderful roadshow at the finals. Frost & Sullivan Frost & Sullivan Wang Chenhui, Managing Partner and Executive Vice President of Frost & Sullivan's Greater China Region, was invited to attend this event and serve as an expert judge. He provided multi-dimensional comments and professional guidance to the participating projects. In the end, 18 The participating project stood out from the finals and won first, second, and third prizes respectively. Managing Partner and Executive Vice President, Greater China, Frost & Sullivan Wang Chenhui Frost & Sullivan helps growth-oriented technology and innovation enterprises Wang Chenhui stated that innovation and entrepreneurship are the core driving forces for enterprise development. Achieving growth is the top priority of enterprise development, while becoming a market leader is a lofty goal for the long-term sustainability of an enterprise. In recent years, Frost & Sullivan has engaged in deep cooperation with industrial development zones across various provinces and cities to achieve mutual benefit. The Nanjing Overseas High-Level Talent Innovation and Entrepreneurship Competition is one of the international exchange and cooperation platforms that Nanjing has been building to serve innovation and entrepreneurship, which aligns very well with Frost & Sullivan's goal of supporting the growth of technology startups. "Frost & Sullivan Global Growth, Tech Innovation and Leadership Summit" (referred to as "Frost & Sullivan Global GIL Summits (‘) have been conducted globally in excess of 20 Countries and regions, with nearly 30 With its 18-year history of hosting, it has successfully attracted the world 1000 Strong participation from leading companies, top domestic and international investment institutions, and other leading enterprises.   It can help them identify opportunities, accelerate growth, innovate continuously, and gain a leadership position in an increasingly complex and changing world. Frost & Sullivan globally GIL The summit begins at 2008 Since its establishment in China in 2019, the event has successfully held sixteen sessions domestically. It has become an important platform for outstanding domestic enterprises, academic institutions, investment experts, and regulatory authorities to exchange successful experiences and jointly explore development directions. It is also a crucial window for the world to understand China's most cutting-edge development trends. Wang Chenhui pointed out, 2021 year 1 month 23 On the same day, the Ministry of Finance and the Ministry of Industry and Information Technology jointly issued the 'Notice on Supporting the High-Quality Development of 'Specialized, Refined, Specialized and Innovative' Small and Medium-Sized Enterprises', launching a policy to support the high-quality development of 'specialized, refined, specialized and innovative' small and medium-sized enterprises with central fiscal funds. As of 2022 At the end of the year, the number of national-level specialized, refined, distinctive and innovative “little giant” enterprises nationwide exceeded 9,000 Home, driving various regions to cultivate provincial-level specialized, refined, characteristic and innovative small and medium-sized enterprises 5 Ten thousand families. 2022 In , Frost & Sullivan proposed   "New investments"   With a brand-new concept, we are dedicated to empowering those enterprises that have already achieved growth or are expected to demonstrate growth, innovation and leadership in the future. At the same time, Frost & Sullivan has specially collaborated with professionals from many institutions including industry, academia, research and investment to establish the "Frost & Sullivan & LeadLeo Innovation Expert Committee". Adhering to the spirit of "many hands make light work",   We aim to achieve high-level collaboration among all stakeholders, support college students' innovation and entrepreneurship, provide integrated service solutions for the development of 'specialized, refined, distinctive, and innovative' enterprises, and help enterprises achieve rapid growth. In addition, Wang Chenhui also said that Frost & Sullivan will leverage tools such as   " Voyager " Program, " Navigator " Program and " Best Practice Award "   By adopting various methods, enterprises can focus on innovation and R&D capabilities, establish effective investment and financing strategies, talent strategies, industrial ecosystems and market layouts, build core competitiveness, achieve deeper-level long-term driving growth, and ultimately empower industrial transformation and upgrading through scientific and technological innovation, promoting China's economic and social development.

2023 Rare Diseases Industry Trend Observation Report Release Conference   On February 25, 2022, as the 2023 Rare Diseases Day approached, the online release conference of the "2023 China Rare Diseases Industry Trend Observation Report" (hereinafter referred to as the "Report") jointly organized by Frost & Sullivan (abbreviated as "Frost & Sullivan") and the Beijing Pain Challenge Public Welfare Foundation (abbreviated as "Pain Challenge Foundation") was successfully held.   The "2023 China Rare Diseases Industry Trend Observation Report" is the second annual trend observation report following last year's joint release by Frost & Sullivan and the Pain Challenge Foundation. The Report aims to review and sort out the development of rare diseases in China in terms of diagnosis, medication, coverage, special medical foods, and innovative services, outline the problems faced and progress made in this field over the past, and propose prospects for China's comprehensive rare disease service system, hoping to be beneficial to policymakers, advocates, practitioners from relevant institutions, patients with rare diseases, and the general public who care about rare diseases.   China's modernization cannot be separated from human health, which also involves the rights and interests of patients with rare diseases, including medication and coverage. Li Linkang, Executive Chairman of the China Rare Diseases Alliance, delivered an opening speech, calling on everyone to respect every rare life, work together to promote the prevention and treatment of rare diseases in China, and light up the light of life for patients with rare diseases. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, attended the release conference and shared insights on the current development status and future trends of the rare disease industry.   The accessibility of rare disease drugs has improved, 70% of therapeutic drugs are included in medical insurance   At the release conference, Guo Jinchuan, Information Research Director of the Pain Challenge Foundation, interpreted the Report from a policy perspective. As of now, based on the "First Batch of Rare Diseases Catalog," 103 drugs have been launched in China, involving 47 rare diseases; among them, 73 drugs have been included in medical insurance, covering 31 rare diseases. However, the coverage of high-value drugs outside the catalog remains a core pain point for patients' medication accessibility, Currently, all treatment drugs for 16 rare diseases are not included in medical insurance, and 13 of these drugs are high-value drugs, with annual treatment costs ranging from hundreds of thousands to millions.   From the national level to local areas, various parties have made extensive explorations to solve the problem of medication accessibility for rare diseases, such as dynamic adjustments to the medical insurance catalog, new exploration of local rare disease medication coverage mechanisms, and the participation of public welfare and charitable forces in multi-level coverage for rare diseases.   Rare diseases have become a popular investment track globally, with multiple favorable policies introduced domestically   Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, stated that currently, patients with rare diseases in China face many difficulties in diagnosis, treatment, payment, and coverage. To solve the urgent medication problem of the rare disease patient group, the Chinese government has introduced six policy measures to encourage the research, development, review, and approval of rare disease drugs: encouraging the research and development of rare disease drugs, prioritizing review and approval, exempting clinical trials, providing tax incentives, and including temporary import and market exclusivity periods.   Mao Hua pointed out that benefiting from favorable policies, China has made certain progress in covering rare disease drug varieties, and domestic pharmaceutical companies are gradually participating in the introduction, research, and imitation of rare disease drugs. Based on the "First Batch of Rare Diseases Catalog," 81 rare disease drugs in China are currently in clinical trials or application stages for marketing, among which 46 drugs are independently developed locally.   On the other hand, the global rare disease field has become a popular investment track, with multinational pharmaceutical companies actively deploying through mergers and acquisitions or research and development cooperation. Data shows that among global pharmaceutical merger and acquisition projects in 2022, rare diseases were the field with the highest capital investment.   In addition, breakthroughs in key technologies have brought new hope to rare disease treatment. Small nucleic acid (SNP) drugs, due to their dual characteristics of gene modification and traditional drugs, have broad application prospects in the field of rare diseases. Currently, there are heavyweight SNP drugs with annual sales exceeding $1 billion in the rare disease field, and more than half of the globally developed SNP drugs are orphan drugs. At the same time, gene therapy also brings hope to patients with rare diseases, with the prices of gene therapies for rare diseases currently on the market often exceeding millions of dollars. China also has many gene therapies for rare diseases under development, but their high prices pose challenges to China's rare disease medication coverage system.   Mao Hua stated that in the future, Frost & Sullivan will continue to follow up on the latest industry trends, pay attention to the field of rare diseases, and continuously release blue books on biomedicine and healthcare industries to help the industry develop healthily and rapidly.   Multiple parties gather to discuss rare disease policies and new directions for the industry   Representatives from policy coverage, industry, and patient organizations gathered together to discuss the direction of rare disease policies and the industry in 2023 based on the Report. The attending guests all emphasized the importance of top-level policy design and took the example of Jiangsu's legislation to determine special fund coverage forms to explore the path of establishing multi-level coverage, hoping to participate in ensuring the last hundred meters of rare disease payment issues through multiple parties to avoid patients with rare diseases missing out on the dividends brought by policies. Industry-related parties also introduced the characteristics of high investment, long cycle, and low short-term returns in rare disease drug research and development, looking forward to more incentive policies.   Finally, everyone expressed their expectations for the Report, hoping to see new changes in the report every year, continuously and intuitively demonstrating the country's attention to rare diseases, benefiting patients with rare diseases, and playing a positive guiding role in the industry.   Frost & Sullivan sincerely looks forward to working with all sectors to pay attention to and jointly ensure the colorful life of the rare disease group; we will also continue to be committed to research in the field of rare diseases, actively fulfill our social responsibilities, and look forward to joining hands with all parties to create a better tomorrow for patients with rare diseases, continuously contributing to the construction of "Healthy China 2030"!   Recommended Reading Scan the QR code below to obtain the report   About Frost & Sullivan's Healthcare Business Unit   The healthcare business unit of Frost & Sullivan has professional analytical capabilities and rich project experience in the field of life sciences. Relying on Frost & Sullivan's global think tank resources and the cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has extensive corporate clients in China and has established a large customer network over the past 20 years, accumulating a wealth of project experience in various healthcare sub-sectors.   Project types include knowledge center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry advisor, clinical audit, fundraising writing), market research, market value management, and strategic consulting, etc., and cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for professional sub-sectors such as pharmaceuticals and medical devices for enterprises, receiving wide attention from investors.

Previously, the registration-based system reform has been piloted on the Sci-tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange. The pharmaceutical and health sector has benefited significantly, with capital vitality injecting momentum into the industry. In particular, the growth momentum in the biopharmaceutical field has been significantly boosted in the past few years.   What is the reference value of the experience gained from the pilot registration-based systems on the Sci-tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange? Especially for biopharmaceutical companies?    What impact does it have on biopharmaceutical companies that are already listed on science and technology innovation boards, entrepreneurship markets, or the Beijing Stock Exchange?    Frost & Sullivan Frost & Sullivan Zhu Yi, Senior Consulting Director of Healthcare Industry in Greater China at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), was interviewed by CBN.com to discuss    The pharmaceutical and health sector under the comprehensive registration-based system reform    . Caijing.com What is the reference value of the experience gained from the pilot registration-based system on the Sci-tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange? Especially for biopharmaceutical companies? After institutions such as the Sci-tech Innovation Board, ChiNext, and Beijing Stock Exchange 4 The cautious pilot implementation in [year] has proven that the registration-based system has withstood the test of the market. With the continuous deepening and improvement of the registration-based reform, the conditions for the full implementation of a registration-based framework and system that suit China's national conditions have matured. In past experience, after the implementation of the stock issuance registration system, there will be a strengthening of the linkage between issuance supervision and continuous supervision of listed companies. This is mainly reflected in three aspects:   1 ) Consolidate the information disclosure responsibilities of listed companies;    2 ) It is conducive to unblocking exit channels such as mandatory delisting and voluntary delisting, and promoting the survival of the fittest among companies; 3 With the establishment and improvement of the transfer board mechanism, the multi-level capital market sector structure has gradually become clear. Therefore, with the implementation of the full registration system, from the perspective of the primary market, the screening and quality control of listed projects will be unprecedentedly strengthened, truly achieving 'strict selection and prioritization' of projects. From the perspective of the secondary market, truly high-quality listed companies will accordingly receive more market attention and valuation premiums. For biopharmaceutical companies, with the full implementation of the registration-based system, these high-growth industries that align with the national strategic development direction are expected to receive policy support. After the launch of the comprehensive registration-based reform, the listing conditions for issuance have become more inclusive, and speculative behavior will be curbed. This is conducive to medium- and long-term holding of high-quality assets, encouraging more entrepreneurs in the life sciences field and those involved in the high-risk, high-return medical industry. At the same time, as a representative industry for high returns and long-term investment, the biopharmaceutical sector will continue to attract long-term capital inflows, which is also more beneficial for the development of biopharmaceutical companies. Q What impact does it have on biopharmaceutical companies that are already listed on science and technology innovation boards, entrepreneurship markets, or the Beijing Stock Exchange? 1 As is well known, the progress of the biopharmaceutical industry is closely related to substantial research and development efforts. With the implementation of the comprehensive registration system, the injection of R&D funds will further introduce fresh vitality into the development of the biopharmaceutical industry. 2 Survival of the fittest, entrusting the issuance dominance to the market. Under the premise of full information disclosure, let the market make its own choices, forming a virtuous game. 3 Going public is no longer the end point of innovation but a new starting point for biopharmaceutical companies.   *    This interview was published on Finance and Economics Network, with reporter Duan Jingyuan.   The original title is    Comprehensive registration-based reform 'projecting' into the pharmaceutical and health sector: balancing speed with price, enjoying dividends with survival of the fittest    》(Click "Read the Original Article" at the end of the text to read the full report).   Recommended Reading   1 Frost & Sullivan executive: The capital market for innovative drugs is warming up, and pharmaceutical companies need to make long-term investments as early as possible with a forward-looking perspective 2 Frost & Sullivan: Currently in clinical development in China ADC drug exceeds 60 One, which will continue to receive attention in the future 3 Frost & Sullivan: Antitumor drugs remain the largest category in healthcare insurance negotiations, with rare diseases and COVID-19 drugs entering the scope of medical insurance to improve patient accessibility   4 Frost & Sullivan executive: 2023 The pharmaceutical industry returns warmly in 2023, with three major areas worthy of attention   5 Frost & Sullivan executive: The healthcare industry will emerge from the winter slump, vaccines are expected to become a potential growth area, and digital transformation will bring new growth drivers to enterprises.

2023 year 2 month 20 On the same day, UN Resident Coordinator in China Constantine Tchoi Tchatchoung, Director of the Investment and Technology Promotion Office of the United Nations Industrial Development Organization Wu Yabin, and Deputy Director General of the Organizing Committee for the Boao Forum on Global Health Luo Xiaoqin inspected Frost & Sullivan ( Frost & Sullivan The Frost & Sullivan China headquarters held talks with Dr. Wang Xin, Global Partner and President of Greater China at Frost & Sullivan, and Yang Xiaocheng, Partner and Managing Director of Greater China, on the friendly cooperation among the three parties in the field of healthy and sustainable development, to jointly contribute to the United Nations 2030 The sustainable development goals are achieved at an accelerated pace.   On February 20, 2023, Mr. Siddharth Chatterjee, United Nations Resident Coordinator in China, Mr. Wu Yabin, Director of the Investment and Technology Promotion Office, United Nations Industrial Development Organization (UNIDO ITPO), and Ms. Andy Luo, Deputy Director of Global Health Forum of Boao Forum for Asia (GHF) Organizing Committee, investigated the Headquarter of Frost & Sullivan China and held talks with Dr. Neil Wang, Global Partner of Frost & Sullivan and President of Greater China, and Mr. Jacky Yang, Partner and Managing Director of Greater China on trilateral partnership and cooperation in the sustainable development field, working together for early realization of UN 2030 Sustainable Development Goals.      

The Ministry of Industry and Information Technology and 17 other departments recently issued the '“Robot + "Implementation Plan for Application Actions", proposing to deepen key areas of "robots". + "Applications. What is the current popularization rate of robots in domestic manufacturing applications? What problems exist? What is the popularization rate of agricultural robots in China? What is the future market space? What are some relatively mature application cases in the healthcare field? Why has most of the commercial robot industry not achieved profitability at present? What impacts does the 'Plan' have on the development of core robot technologies?" Frost & Sullivan Frost & Sullivan Cui Nan, Executive Director of Frost & Sullivan Greater China Region (hereinafter referred to as 'Frost & Sullivan'), was a guest at the Finance Program Center of China Media Group & CCTV.   Industry Investment Observation   The securities radio program discusses the development of the robotics industry together. CCTV Financial Program Center   Q The Plan proposes up to 2025 In [year], the manufacturing robot density was relatively 2020 The number of services robots and special-purpose robots has doubled year-on-year, with a significant improvement in both depth and breadth of industry applications. As you know, what is the current popularization rate of robots in domestic manufacturing? What problems exist? At present, the aging trend in our country continues to intensify, and it is expected that the labor force population will also show a downward trend in the future. Coupled with the increasing cost of labor, this has continuously increased the development pressure on manufacturing. Therefore, accelerating the development of automation applications represented by industrial robots has become an urgent task. In the past decade, China has deeply implemented intelligent manufacturing projects, and the scale and level of intelligent manufacturing applications have entered the global leading ranks. The robot density in China's manufacturing industry has increased by about 13 times, reaching an average of 10,000 workers 322 Industrial robots, 5G The application scale of key intelligent manufacturing technologies such as artificial intelligence has remained at the forefront globally.   China's manufacturing industry has unique advantages in promoting transformation and upgrading by applying industrial robots.    Currently, China has the world's largest engineering talent pool, the greatest manufacturing demand, a wider range of industrial robot application scenarios, a more agile industrial chain response speed, a complete robot industry system, and a leading digital economy industry scale. China's manufacturing sector is the world's largest demand market for industrial robots and the most ideal application testing ground. In particular, the vast manufacturing system has also enabled domestic enterprises to have a deeper understanding of industrial robot application scenarios, strengthening the capabilities of many manufacturing enterprises to develop and manufacture industrial robots in niche fields.   At present, over a hundred factories in China have reached the international advanced level of intelligent manufacturing, with main business revenue exceeding 10 There are nearly a hundred intelligent manufacturing system solution providers worth hundreds of millions, with service scopes covering 90% The above manufacturing sectors.   However, there is still significant room for improvement in the current manufacturing robot density in China, and the penetration rate of robots in manufacturing also needs to be further strengthened.   On the one hand, there are 'bottleneck' risks regarding domestic technological breakthroughs in industrial robots, localization substitution, and the security of the robot industry supply chain.   Affected by various factors, some developed countries will not only further strengthen restrictions on the export of complete high-end industrial robots to China but also increase scrutiny over Chinese robot manufacturers' procurement of key core components, limit patent and technology transfers. Whether it is for the transformation and upgrading of the domestic robotics industry or for manufacturing enterprises using high-end industrial robots, the resistance will further increase in the future. However, with the increased R&D investment by Chinese related enterprises and institutions, breakthroughs have been made in some core component areas. The localization and substitution of some core components for industrial robots are accelerating, and robot industry clusters have formed on a certain scale in some regions. The development of the new generation of robot industries, which are closely integrated with artificial intelligence technology, is also providing opportunities for China's robot industry to catch up and surpass.   On the other hand, for China's manufacturing industry to achieve the goals of machine replacing manual labor and human-machine collaboration, it not only needs to make technological breakthroughs but also faces a complex employment environment that requires supporting reforms to the education system.   In recent years, some manufacturing industries in our country have faced labor shortages. At the same time, there are also phenomena of underemployment and insufficient employment. The use of industrial robots should not only fill the employment gaps in manufacturing and reduce labor costs in manufacturing, but also create new job opportunities in other more suitable industries and fields. Q In terms of agriculture, the 'Plan' proposes to promote the deep integration of robots with agricultural planting, breeding, forestry, and fisheries production, supporting the development of smart agriculture. What is the current popularization rate of domestic agricultural robots? How is the future market space analyzed?   The mechanization rate of agricultural facilities in China is only 30% Left and right, the penetration rate of agricultural robots is even lower. Compared with developed countries, in addition to environmental control systems, the overall level of automated and intelligent equipment for facility cultivation is not high, and there is still a certain gap. Most domestic agricultural robots with independent intellectual property rights are still in the prototype stage, and there is still a certain gap in terms of precision, efficiency, and reliability compared with foreign manufacturers.   There are two main bottlenecks in the promotion and popularization of agricultural robots in our country: one is the manufacturing cost of agricultural robots, and the other is the level of intelligence of agricultural robots. Currently, most developed agricultural robots are only designed for a specific task within a certain stage of agricultural production. However, one characteristic of agricultural production is its strong seasonality, which leads to low utilization efficiency of agricultural robots and indirectly increases their operating costs. The cost-effectiveness of these robots cannot meet market needs, becoming a bottleneck that restricts the commercialization and further research and application of agricultural robots. For example, in the case of picking robots, due to the seasonal nature of some cash crops, if picking robots can only be used for picking one type of crop, then the robot's working hours per year are very limited. Only when the operating cost of agricultural robots is lower than that of manual labor can they be widely promoted, which undoubtedly poses high requirements for cost control of agricultural robots. Compared to industrial robots or robots in other fields, agricultural robots operate in a variety of environments, mainly unstructured ones, and their tasks pose significant challenges. Therefore, generally speaking, agricultural robots have much higher requirements for intelligence than robots in other fields. At present, the field of agricultural engineering has shifted its research focus from mechanical studies to machine vision and artificial intelligence technology research, aiming to solve the intelligence problems of agricultural robots. From the current technical level, mature solutions have been developed in areas such as automatic navigation and visual recognition positioning. However, overall, the development of intelligent systems is not yet perfect, and many tasks cannot be completed solely by agricultural robots. On the other hand, even if agricultural robots have achieved a considerable level of intelligence and can perform certain tasks, their manufacturing costs are too high, making development extremely difficult and making them difficult to be commercially applied on a large scale. From the current research status, agricultural robots can replace some of the labor done by humans and have very high work efficiency. For tasks that are harsh on the environment, require heavy physical labor, or involve repetitive and monotonous work, such as spraying pesticides, harvesting, and crop sorting, it is expected that agricultural robot systems will be able to complete these tasks, thereby liberating a large amount of human resources. With the continuous rapid development of China's national economy, the adjustment of agricultural industrial structure, the intensification of agricultural production, and the rapid development of robot technology in our country, there will be good development opportunities for China's agricultural robotics industry. In the application of new agricultural production models and technologies, agricultural robots, as a new generation of intelligent agricultural machinery, will surely be used more and more widely. China is a developing agricultural country, and agricultural issues have always been fundamental to the socio-economic development of society. Among them, agricultural science and technology are currently the main driving force for agricultural growth. In future agricultural development, the widespread application of agricultural robots to replace resources with technology, improve resource utilization and agricultural output rates, thereby enhancing economic benefits, will be an inevitable trend in modern agricultural development. Therefore, research and development related to agricultural robots are of great significance for the long-term development of agriculture in China.   Q Medical health is also a key application area for robots. What are some relatively mature use cases in your opinion at present?   Currently, relatively mature applications include hospital delivery robots and clinical medical robots. Hospital delivery robots, with mobile robots as carriers, implement an autonomous guided unmanned automated handling system. In traditional hospital scenarios, the transfer of various items within the hospital is mainly carried out by patients, medical staff, or dedicated delivery personnel. There is a lack of clear distinction between pedestrian flow lines and logistics flow lines, leading to serious cross-over between them. This often results in chaos in both pedestrian and logistics traffic, posing potential risks of cross-infection among different personnel, as well as contamination, damage, and loss of items. Against the backdrop of past epidemics, the application value of delivery robots in scenarios such as hospitals has gradually become rapidly apparent. Intelligent delivery robots mainly undertake tasks within the hospital campus such as delivering medications and meals to isolation areas, as well as collecting bedding and medical waste. Through the intelligent scheduling of the central control center, robots can perform functions such as independently opening and closing doors, taking elevators on their own, avoiding obstacles, and charging themselves without human operation. Some robot boxes are equipped with ultraviolet disinfection lamps to keep the box and items clean at any time. Robots also have remote real-time voice and video communication capabilities, allowing direct communication with nurses or patients in isolation wards through the scheduling system. Medication delivery robots can replace nurses in completing daily tasks such as delivering medications, case files, and laboratory test reports. Clinical medical robots include surgical robots and diagnostic and therapeutic robots, capable of performing precise surgeries or diagnoses. The industry is most well-known for the 'Da Vinci' robot, whose success is also due to its adoption by the United States and Europe. FDA Approved for clinical use; some leading domestic companies have also obtained the approval from the China Food and Drug Administration ( CFDA The surgical robot medical device registration license issued by the relevant authority has been applied in fields such as trauma orthopedics and spinal surgery. Q In terms of service robots, the Plan proposes Commercial community service develops commercial robots for catering, delivery, reception, guided tours, consulting, cleaning, mobility assistance, etc., as well as household robots for cooking, cleaning, monitoring, companionship, and more. However, most commercial robot companies in the industry have not yet achieved profitability. What are the reasons?   1 The R&D cost of commercial robots is high, and the industry is still in an early stage focusing on heavy investment in research and development. The high R&D costs lead to financial losses; 2 Commercialization is in the exploration phase, and appropriate business models are being gradually explored through continuous development. Certain market education efforts have been carried out, resulting in a limited commercial application scale of commercial robots, with limited commercial revenue. 3 Against the backdrop of the pandemic over the past three years, many downstream industry customers of commercial robots have been impacted themselves. For example, multiple industries such as catering, hospitality, and tourism have suffered negative effects, which has also had a negative impact on the downstream procurement demand for commercial robots. Q In terms of household robots, the penetration rate of cleaning-related products is relatively high. Which products still need to be broken through and what are the challenges? individual / Home service robots enter home life through multiple functions. Among them, assisting with household chores is the most mature branch of service robots at present. In the future, service robot manufacturers will focus on areas such as family education, entertainment, and companionship robots. The challenges include the need to improve technical standards. Currently, in addition to floor sweeping robots, there are personal / The hardware level and intelligence of home service robots need further improvement. To achieve this, profound technical capabilities and cost-effective product implementation solutions are required. Secondly, the current individual / The market for home service robots is highly homogenized. In the face of a highly homogeneous market, how to build brand barriers and develop innovative and differentiated products is a question that companies in the industry need to seriously consider.   Q The 'Plan' supports user units to participate in the core technology research and development of the robot industry chain, including high-torque density servo motors, high-dynamic motion planning and control, and human-machine interaction. It aims to deeply explore and unleash potential application demands, and jointly develop advanced and applicable robot products and system solutions. What impacts will this have on the development of core robot technologies?   The situation in which China has long been constrained by others in key components such as reducers, servo motors, and controllers is changing. Domestic manufacturers have successively overcome some difficulties in these core component areas and are steadily advancing the localization of these components. This will reduce the cost of domestic robots, increase their proportion in new installations, and more importantly, it will break the technological development constraints imposed by foreign brands in key areas. Artificial intelligence, situated in the third wave of rapid development, has opened up vast prospects for a new generation of robots. New intelligent service robot technologies are increasingly focused on big data, the Internet of Things, perception systems, and other fields. In these areas, China is almost on par with foreign countries, and in some technologies and market application spaces, China even holds an advantage. This will bring significant opportunities for China's robots to achieve 'curve overtaking'. To promote the innovative development of China's robotics industry, efforts can be focused on the following aspects:   First, achieve self-reliance and control over the domestic supply chain to ensure industrial security.   After tackling key issues during the 12th and 13th Five-Year Plans, robot core components (reducing gears, servo motors and drives, controllers) have been commercialized and mass-produced domestically, with the localization rate of harmonic reducers exceeding 65% Robotic-specific sensors have been commercialized, initially enabling small-scale applications. The core component industry has achieved phased results, cultivating several backbone enterprises in this field. However, it cannot be ignored that robot operating systems and digital twin software are still in their infancy, and robot general-purpose chips, some sensor-specific chips, and robot R&D design software still face risks of supply interruption and slowdown.   Achieving the localization of core software and components for robots, as well as building a high-quality supply chain, is the focus of the healthy development of the robotics industry.   Secondly, cultivate leading enterprises and 'specialized, refined, distinctive, and innovative' (SRII) enterprises to enhance industrial competitiveness.   The competitiveness of Chinese robotics enterprises is the decisive force determining our voice in the global robotics industry landscape. After 60 Year-on-year development, cultivation of ABB , KUKA Giant industrial robot companies have also cultivated a group of hidden champions. It should be said that leading enterprises and hidden champions truly dominate and lead the development direction of the robotics industry. For the robotics industry in our country to achieve high-quality development, it is necessary to cultivate two or three world-class robot companies with global competitiveness, as well as a number of specialized and innovative enterprises with leading advantages in niche fields.   Thirdly, it is necessary to create a favorable industrial ecological environment to achieve sustainable and healthy industrial development.   Efforts should be made to strengthen the construction of an industrial innovation system, establishing a technology innovation system that is enterprise-oriented, market-driven, and deeply integrated with industry, academia, and research. Promote the construction of national-level technology innovation centers, industrial innovation centers, and manufacturing innovation centers in the field of robotics, and build open, collaborative, and efficient common technology research and development platforms. Cultivate a large number of strategic scientific and technological talents, leading scientific and technological talents, and high-level innovation teams with international standards. At the same time, attention should be paid to cultivating applied and skilled vocational talents. Promote the healthy interaction between capital and industry, accelerate the incubation of new robot technologies, products, and models through government guidance and market-oriented operations. Establish a system that adapts to the development of the robotics industry, build an industrial standardization system, and establish and improve technical standards for basic commonality, interconnection, security privacy, industry applications, etc. Lead the new standards and models of intelligent manufacturing for robots, promote the integrated application of new-generation robots, core supporting software, industrial Internet, etc., popularize new manufacturing models such as process intelligent manufacturing, discrete intelligent manufacturing, networked collaborative manufacturing, remote diagnosis and operation and maintenance services based on new-generation robots, and support the transformation and upgrading of the national manufacturing industry.   * The program has been broadcast on third-party platforms under the title '“Robot + "Empowering thousands of industries: accelerating the promotion of robot applications".   Recommended Reading   1 Dr. Xin Wang from Frost & Sullivan: With multiple advantages at its disposal, the Chinese market will become increasingly attractive to foreign capital   2 Frost & Sullivan: It is expected that the supply-demand gap in the civil shipbuilding industry will continue to widen, driving the industry towards a state of both volume and price increases.     3 Frost & Sullivan: It is expected that industries in high-growth sectors such as electronics, power equipment, and pharmaceutical biotechnology will continue to maintain robust growth.   4 Frost & Sullivan: The Chinese gaming market has moved from an era of extensive volume growth to one of building a high-quality gaming moat, and the localization process for game developers still has a long way to go   5 Frost & Sullivan: China has become the world's largest consumer and importer of cherries, but per capita consumption is still relatively low.   

With the continuous development of molecular biology technology, nucleic acid drugs have also attracted significant attention due to their tremendous potential in disease diagnosis and treatment. Compared to traditional small molecule drugs and antibody drugs, nucleic acid drugs can fundamentally regulate the expression of pathogenic genes, offering clear advantages such as simple design, short development cycle, strong targeting specificity, a wide range of therapeutic fields, and long-lasting effects. Currently, they are widely used in the treatment of genetic diseases, tumors, viral infections, and other diseases, making them one of the most promising areas in biopharmaceutical research and development today. 2023 year 2 month 17 On the 1st, co-hosted by Danahelix Life Sciences and organized by Yimao Medical, the event “Focus on Frontiers, Boost Innovation -2023 The 'Nucleic Acid Drug Developers Summit ” was held in Shanghai. This forum focused on nucleic acid drug development, CMC The challenges faced by process quality and the subsequent commercialization are aimed at providing strategies to promote the innovative development of China's nucleic acid drug industry. Frost & Sullivan Frost & Sullivan Mao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event. He delivered a speech on the current situation and future prospects of the nucleic acid drug market and served as the moderator for the guest interviews. He also had discussions with Zhang Peizhuo, Chairman and Chief Scientist of Jimay Gene, Yuan Jijun, Executive Vice President of Aibo Biotech, and Vice President of Darui Biotech. & Co-founders Huang Jinyu and Jian Xin Yuanli CDMO company Zhu Min, Senior Vice President of Operations, joined us to discuss the next phase of nucleic acid drug development from research and development to industrialization. Partner and Managing Director of Frost & Sullivan Greater China Region fattening Mao Hua first briefly introduced the current development status of the nucleic acid drug industry to the attending guests.   He pointed out that nucleic acid drugs are targeted at long duration, designed simply, and have a rich array of candidate targets, promising to become the third major type of drug following small molecule and antibody drugs.   As of now, there are a total of 12 model (excluding 3 Products that have been delisted), already listed 2 model mRNA Drugs are essentially vaccines. Approved drugs are mostly used for the treatment of rare diseases and the prevention of COVID-19. With the expansion of indications and the continuous development and improvement of technology platforms, the sales of nucleic acid drugs show a growth trend. At the same time, multinational pharmaceutical companies have also been actively deploying nucleic acid drugs in recent years, covering a wide range of disease areas including cardiovascular, hepatitis B, neurological, metabolic, and oncology. The data shows, 2017 Year-end 2021 In [year], the global market scale of nucleic acid drugs has grown from 10 USD billion growth to 620 billions, with an average annual compound growth rate exceeding 180% .   Mao Hua said that with the continuous maturity and commercial success of related key technologies, driven by policy support, multi-party R&D cooperation, and capital investment, the nucleic acid drug market has great potential. Subsequently, Mao Hua analyzed small nucleic acid drugs and mRNA Research progress and trend prospects of vaccines and drugs. According to its introduction,   In the field of small nucleic acid drugs,   Currently available 127 The drug is in clinical and Non-Disclosure Agreement Stage, mainly comprising ASO and RNAi drugs, and most are still I period and II Phase clinical stage. In terms of therapeutic areas, the research and development (R&D) projects for small nucleic acid drugs mainly focus on anti-tumor, nervous system, cardiovascular and cerebrovascular fields. There are fewer R&D projects for small nucleic acid drugs targeting the immune system, skin, and hormones, and more than half of the R&D projects for small nucleic acid drugs are orphan drugs.   Mao Hua said that in the future, the small nucleic acid drug market will develop towards trends such as technological innovation, expansion of market scale and demand, multi-party collaboration, industrial clusters, and increasingly complete R&D capabilities. According to a study by Frost & Sullivan,   at mRNA Vaccines and pharmaceuticals   Currently, there are 77 The drug is in clinical development, mainly comprising mRNA vaccines, and most are still I period and II Phase clinical stage. In terms of therapeutic domains, mRNA Vaccine and drug research projects are mainly focused on areas such as anti-tumor therapy and treatment of infectious diseases. LNP The most widely used delivery system. Mao Hua pointed out that the COVID-19 pandemic has accelerated it mRNA With the popularization and commercialization of technology, countries have increased their investment in mRNA The investment in technology has promoted mRNA Construction and improvement of the technology platform.   In the future, as technology applications gradually mature, it is expected mRNA The fields of vaccine and drug treatment will continue to expand, with the R&D system gradually becoming complete. The efficacy and safety will also be continuously improved. The industry will achieve synchronous development and win-win cooperation. Learn more about the nucleic acid drug market Scan the QR code below to obtain the presentation report. About Danaher Life Sciences Danaher is an innovator in the global life science service sector, dedicated to helping customers accelerate research in the field of life sciences with high-quality products and services. It addresses problems and challenges encountered in the analytical domain, promotes the development of medical diagnostics, and enhances laboratory productivity. The China region of Danaher Life Sciences was established in 2019 year 6 month 1 Today, aiming to take root in the Chinese market and provide better products and services for Chinese users, with the philosophy of 'Focusing on Life, Working Together for a Win', and taking 'Sharing Global Technology to Achieve National Health' as its mission, we strive to create comprehensive integrated solutions for precision medicine and biopharmaceuticals. About Frost & Sullivan's Healthcare Practice The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences field. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China, and in the past 20 In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.